Extended Data Figure 6|. Neoantigen quality is independently prognostic of survival.

a, Overall survival of patients whose tumors displayed high compared to low neoantigen quality (Neoantigen Quality^Hi/Low) (top left). Overall survival of patient who did or did not receive adjuvant chemotherapy (top right). Overall survival of all four groups is shown at the bottom. Neoantigen quality defined by pipeline and schema as defined in Extended Data Figure 5a, b. Table shows univariate and multivariate Cox regression analysis of the associations of clinicopathologic features, adjuvant chemotherapy, and neoantigen quality with overall survival. Data include all patients in the whole exome sequencing MSKCC cohort. b, Number of nonsynonymous, missense, and neoantigenic mutations per patient in the ICGC cohort (n=166). c, Overall survival of patients in the ICGC cohort whose tumors displayed high compared to low neoantigen quality (Neoantigen Quality^Hi/Low) (top left). Overall survival of patients in the ICGC cohort stratified by adjuvant chemotherapy administration (top right). Overall survival of all four groups shown in bottom. Neoantigen quality defined by pipeline and schema as defined in Extended Data Figure 5a, b. Table shows univariate and multivariate Cox regression analysis of the associations of clinicopathologic features, adjuvant chemotherapy, and neoantigen quality with overall survival in the ICGC cohort. n = biologically independent samples in individual patients. P-values were determined using log-rank test (a, c).